Corvus Pharmaceuticals is a clinical stage biopharmaceutical company focused on the development of immune modulator product candidates to treat solid cancers, T-cell lymphomas, autoimmune diseases and infectious diseases. Co.'s lead product candidate is mupadolimab, a humanized monoclonal antibody that is designed to react with a specific site on CD73. Co.'s next product candidate, CPI-818, is a selective, covalent inhibitor of ITK and is in a multi-center Phase 1/1b clinical trial in patients with various malignant T-cell lymphomas. Co.'s third product candidate, ciforadenant, is an oral, small molecule antagonist of the A2A receptor for adenosine. The CRVS average annual return since 2016 is shown above.
The Average Annual Return on the CRVS average annual return since 2016 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether CRVS average annual return since 2016 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the CRVS average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|